|Company:||Vertex Pharmaceuticals Incorporated|
|Class Period:||May-7-12 to Jun-27-12|
|Lead Plaintiff Deadline:||Dec-21-12|
|Court:||District of Massachusetts|
On May 7, 2012, Vertex issued a press release claiming that patients who received two of its drugs during clinical trials showed significant improvement in their lung functions. Between May 7, 2012 and May 25, 2012, certain Vertex officers and directors sold over $22 million of their personally owned shares. Then, on May 29, 2012, Vertex issued a series of press releases in which it acknowledged that the results from its clinical trials were not as positive as previously indicated. These results were further restated on June 28, 2012. Upon this news, Vertex stock fell from a close of $61.11 on June 27, 2012, to a close of $51.18 on June 28, 2012.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.